The Frank W. Fitch Monoclonal Antibody Facility at the University of Chicago provides a wide range of services focusing on the generation and production of monoclonal antibodies. Since the development of hybridoma technology more than thirty years ago, the use of monoclonal antibodies that have defined specificities has become an essential tool in the rapidly growing interdisciplinary approach to biomedical technology and research. Consequently, the generation and proper manipulation of monoclonal antibodies can be critical to the successful outcome of a particular project. Since its inception in 1995, the Facility has gained extensive experience in all areas related to the production of monoclonal antibodies from developing unique immunization schedules to customized ELISA screening of subclones. Facility personnel work closely with investigators and their staff in order to derive monoclonal antibodies specifically suited to their needs. This personal attention and interaction, together with a modest fee structure, makes using the Facility a reasonable option to the prohibitive charges of most commercial vendors. During the current funding period, the Facility has served UCCRC members by generating antibodies against a diverse array of proteins. Antibodies are utilized by investigators to assess such things as the degree of malignancy of intestinal epithelial cells, the identification of T cells subsets at various phases of the immune response, or the levels of cytokines which can confer resistance to tumor viruses. The Facility also offers large-scale production of high titer antibody supernatant using bioreactor technology, conjugation of antibodies to FITC and biotin, and the development and optimization of ELISAs. New services in the Facility include assistance in the creation of custom ELISAs to be used in the investigator's laboratory, customized fusions to obtain monoclonals for DNA analysis, subcloning of hybridomas to obtain and maintain stocks of cells that are producing antibody at maximum levels and, most recently, assistance in problem-solving the difficult task of purifying IgM antibodies. The Facility's dedicated staff and Scientific Advisor are committed to continuing to provide Cancer Research Center members and the entire University community with convenient, high-quality, and cost-effective services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-34
Application #
7843303
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
34
Fiscal Year
2009
Total Cost
$78,942
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5

Showing the most recent 10 out of 668 publications